Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Skye Bioscience Inc (OP: SKYE ) N/A UNCHANGED Last Price Updated: 3:57 PM EDT, Apr 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Skye Bioscience Inc < Previous 1 2 Next > Skye Bioscience Announces $40 Million Private Placement Equity Financing March 11, 2024 San Diego, California--(Newsfile Corp. - March 11, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) (the Company), a clinical stage biotechnology... Via Newsfile Skye Bioscience to Present at Oppenheimer Investor Conference February 07, 2024 San Diego, California--(Newsfile Corp. - February 7, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a clinical-stage biotechnology company focused... Via Newsfile Skye Bioscience Announces $50.25 Million Private Placement Equity Financing January 29, 2024 San Diego, California--(Newsfile Corp. - January 29, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("the Company"), a clinical stage biotechnology... Via Newsfile Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease January 09, 2024 San Francisco, California--(Newsfile Corp. - January 9, 2024) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa December 05, 2023 San Diego, California and Johannesburg, South Africa--(Newsfile Corp. - December 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a... Via Newsfile Topics Cannabis Intellectual Property Exposures Cannabis Intellectual Property Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit November 21, 2023 San Diego, California--(Newsfile Corp. - November 21, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing drugs... Via Newsfile Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma October 25, 2023 • SBI-100 OE is well tolerated, with low rate of hyperaemia... Via Newsfile CORRECTION: Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System" October 20, 2023 This document replaces and updates the previous version with the current OTCQB ticker for Skye Bioscience, Inc.San Diego, California--(Newsfile Corp.... Via Newsfile Skye Bioscience to Present at H.C. Wainwright 25th Annual Global Investment Conference September 05, 2023 San Diego, California--(Newsfile Corp. - September 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing proprietary... Via Newsfile Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody August 21, 2023 New capital funds anticipated Phase 2a glaucoma clinical trial Nimacimab is a first-in-class peripherally-restricted negative allosteric modulator antibody inhibitor of... Via Newsfile Skye Bioscience to Present at H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference August 14, 2023 San Diego, California--(Newsfile Corp. - August 14, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a pharmaceutical company developing a... Via Newsfile Skye Bioscience Receives Positive Safety Review for Final Cohort of Fully-Enrolled Phase 1 Study of SBI-100 Ophthalmic Emulsion July 13, 2023 San Diego, California--(Newsfile Corp. - July 13, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial July 06, 2023 San Diego, California--(Newsfile Corp. - July 6, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion June 12, 2023 San Diego, California--(Newsfile Corp. - June 12, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience to Present at LD Micro Invitational XIII June 05, 2023 San Diego, California--(Newsfile Corp. - June 5, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Receives Positive Safety Review of Fifth Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion June 02, 2023 San Diego, California--(Newsfile Corp. - June 2, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Topics Derivatives Exposures Derivatives Skye Bioscience Begins Dosing Fifth of Six Cohorts in Phase 1 Clinical Trial of Novel CB1R Agonist May 17, 2023 San Diego, California--(Newsfile Corp. - May 17, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion May 15, 2023 San Diego, California--(Newsfile Corp. - May 15, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Begins Dosing Phase 1 Fourth Cohort in Clinical Trial of Novel CB1R Agonist April 27, 2023 Skye progresses to multiple ascending dose arm of SBI-100 Ophthalmic Emulsion trial after completing single ascending dose armP1 dosing of... Via Newsfile Skye Bioscience Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion April 04, 2023 San Diego, California--(Newsfile Corp. - April 4, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Topics Derivatives Exposures Derivatives Skye Bioscience's Novel Cannabinoid Derivative Reduces Pain in Animal Model; Results Published in Scientific Journal April 03, 2023 San Diego, California--(Newsfile Corp. - April 3, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Topics Cannabis Exposures Cannabis Skye Bioscience Receives Human Research Ethics Committee Approval to Start Multiple Ascending Dose Arm of Phase 1 Study of SBI-100 Ophthalmic Emulsion March 15, 2023 San Diego, California--(Newsfile Corp. - March 15, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion March 07, 2023 San Diego, California--(Newsfile Corp. - March 7, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Topics Derivatives Exposures Derivatives Skye Bioscience Receives Positive Safety Review of SBI-100 Ophthalmic Emulsion After Second Cohort of Phase 1 Study February 23, 2023 San Diego, California--(Newsfile Corp. - February 23, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors February 16, 2023 San Diego, California--(Newsfile Corp. - February 16, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment February 15, 2023 San Diego, California--(Newsfile Corp. - February 15, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Topics Cannabis Exposures Cannabis Skye Bioscience Doses Second Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion February 13, 2023 San Diego, California--(Newsfile Corp. - February 13, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion February 02, 2023 San Francisco, California--(Newsfile Corp. - February 2, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Topics Derivatives Exposures Derivatives Skye Bioscience Achieves Positive Safety Review of SBI-100 Ophthalmic Emulsion After Phase 1 First Cohort January 31, 2023 San Diego, California--(Newsfile Corp. - January 31, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion January 27, 2023 San Diego, California--(Newsfile Corp. - January 27, 2023) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... Via Newsfile Exposures Product Safety < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.